Your browser is no longer supported. Please, upgrade your browser.
BIIB Biogen Inc. daily Stock Chart
Biogen Inc.
IndexS&P 500 P/E9.85 EPS (ttm)31.47 Insider Own0.10% Shs Outstand174.03M Perf Week-7.89%
Market Cap53.96B Forward P/E9.59 EPS next Y32.35 Insider Trans-0.60% Shs Float172.98M Perf Month9.98%
Income5.89B PEG2.62 EPS next Q7.83 Inst Own91.10% Short Float1.80% Perf Quarter2.47%
Sales14.38B P/S3.75 EPS this Y44.80% Inst Trans-4.60% Short Ratio1.75 Perf Half Y40.44%
Book/sh75.05 P/B4.13 EPS next Y-0.62% ROA21.90% Target Price331.26 Perf Year-5.72%
Cash/sh25.72 P/C12.06 EPS next 5Y3.76% ROE43.50% 52W Range215.77 - 374.99 Perf YTD4.50%
Dividend- P/FCF8.22 EPS past 5Y20.50% ROI30.50% 52W High-18.21% Beta1.32
Dividend %- Quick Ratio1.60 Sales past 5Y8.20% Gross Margin86.40% 52W Low42.15% ATR10.75
Employees7400 Current Ratio1.70 Sales Q/Q4.10% Oper. Margin49.00% RSI (14)43.05 Volatility2.81% 4.28%
OptionableYes Debt/Eq0.45 EPS Q/Q66.70% Profit Margin41.00% Rel Volume0.91 Prev Close310.08
ShortableYes LT Debt/Eq0.33 EarningsJan 30 BMO Payout0.00% Avg Volume1.78M Price306.71
Recom2.70 SMA20-4.46% SMA500.86% SMA20017.58% Volume1,252,846 Change-1.09%
Feb-27-20Initiated Barclays Overweight $389
Jan-27-20Upgrade Canaccord Genuity Hold → Buy $360
Dec-13-19Upgrade Credit Suisse Underperform → Neutral $260 → $300
Dec-02-19Downgrade Robert W. Baird Neutral → Underperform
Nov-12-19Initiated SunTrust Buy $337
Nov-01-19Downgrade Standpoint Research Buy → Hold
Oct-30-19Upgrade Bernstein Mkt Perform → Outperform
Oct-23-19Upgrade SVB Leerink Mkt Perform → Outperform $256 → $350
Oct-23-19Upgrade Guggenheim Neutral → Buy $256 → $365
Oct-23-19Reiterated H.C. Wainwright Buy $300 → $335
Oct-23-19Reiterated BofA/Merrill Underperform $200 → $235
Oct-17-19Resumed BofA/Merrill Underperform $200
Jun-28-19Downgrade Piper Jaffray Overweight → Neutral $280 → $250
Jun-05-19Upgrade Standpoint Research Hold → Buy
May-23-19Resumed Citigroup Neutral
May-23-19Initiated Wedbush Neutral
May-21-19Initiated Credit Suisse Underperform $198
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Feb-28-20 11:35AM  What A Biogen Deal Means For This Small Genetic Medicines Outlet Investor's Business Daily
11:08AM  Sangamo Stock Is Soaring on Plan to Collaborate With Biogen
08:00AM  Biogen's Roller Coaster Continues In 2020 Is BIIB Stock A Buy? Investor's Business Daily
07:28AM  The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO Benzinga
06:34AM  Biogen pays California biotech $350M upfront for Alzheimer's gene therapy American City Business Journals
Feb-27-20 04:06PM  Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimers, Parkinsons, Neuromuscular, and Other Neurological Diseases GlobeNewswire -5.30%
Feb-25-20 07:53AM  Top Health Care Stocks for March 2020 Investopedia
Feb-20-20 09:34AM  Zacks Market Edge Highlights: Tesla, Micron, Biogen, GameStop and Maxar Technologies Zacks
Feb-18-20 03:32PM  16 Stocks Warren Buffett Is Buying and Selling Kiplinger
12:00PM  Wanna Be a Value Investor? Follow Buffett & Play 2 ETF Areas Zacks
10:00AM  Kroger Climbs on Warren Buffett Endorsement
06:13AM  Warren Buffett's Berkshire Hathaway Trims Apple Stake, Buys Into Kroger, Biogen Benzinga
Feb-17-20 06:48PM  Berkshire Hathaway Buys The Kroger Co, Occidental Petroleum Corp, Biogen Inc, Sells Wells Fargo ...
05:00AM  Buckingham's Bets in Biotech MoneyShow
Feb-14-20 07:58PM  Warren Buffett's Berkshire Hathaway Takes Stakes in Kroger, Biogen; Cuts Banks and Apple
06:13PM  Warren Buffett Buys Kroger, Biogen in 4th Quarter
05:28PM  Buffetts Berkshire Adds Biogen, Kroger Stakes; Stocks Climb Bloomberg
05:26PM  Warren Buffetts Berkshire Hathaway Bought Biogen, Kroger, Occidental Stock
05:11PM  Warren Buffett Made Some Surprising Buys And Sells For Berkshire Hathaway In Q4 Investor's Business Daily
04:55PM  Berkshire Hathaway starts position in Biogen, Kroger while trimming Travelers MarketWatch
09:02AM  Vertex Is the Top Big Biotech, According to Citi. 3 More Stocks It Says to Buy.
Feb-13-20 11:00AM  3 Undervalued 'Magic Formula' Stocks
Feb-11-20 10:33AM  These Pharma Giants Took A Hit On Two More Alzheimer's Failures Investor's Business Daily
09:12AM  Lilly Reports Disappointing Data on Alzheimer's Candidate Zacks
Feb-10-20 09:28AM  Alkermes (ALKS) to Report Q4 Earnings: What's in Store? Zacks
09:19AM  Lilly and Biogen Stocks Get Hit as Another Alzheimers Treatment Fails a Trial
08:01AM  Lilly's stock falls on failed Alzheimer's study MarketWatch
12:49AM  Roche and Eli Lilly drugs fail inherited Alzheimers trial Financial Times
Feb-08-20 07:00AM  Playing With Fire: Teslas Wild Week Gets Hearts Pumping on Wall Street Bloomberg
Feb-07-20 02:45PM  Top Stock Research Reports for Alphabet, Roche & Amgen Zacks
02:41PM  Edited Transcript of BIIB earnings conference call or presentation 30-Jan-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-06-20 04:08PM  This Biotech Stock Fell, Then Rose, And Prodded Biogen Into A Two-Day Run Investor's Business Daily
11:53AM  Biogen Soars on Patent Win for MS Drug Tecfidera Over Mylan Zacks
09:15AM  S&P, NASDAQ Reach New Closing Highs on 3rd Day of Rally Zacks
06:37AM  Biogen shares rise as drugmaker avoids worst case scenario in patent dispute American City Business Journals
Feb-05-20 04:22PM  US STOCKS-S&P 500, Nasdaq mint record highs after strong U.S. data, waning virus fears Reuters +17.50%
04:21PM  Biogen Rockets Into A Breakout After Beating Mylan In A Patent Battle Investor's Business Daily
04:03PM  In the highest ranks of Mass. corporate leadership, women still scarce American City Business Journals
03:22PM  US Stocks in the Green on Wednesday
03:16PM  Biogen Beats Back Mylan Patent Challenge Over MS Drug Tecfidera
03:02PM  US STOCKS-Wall St gains after strong US data, waning virus fears; Tesla limits Nasdaq's rise Reuters
02:59PM  Biogen's stock jump 19% on Tecfidera patent ruling MarketWatch
02:48PM  Biogens $11 Billion Boom Erases 2019 Alzheimers Drug Struggle Bloomberg
02:13PM  Biogen Stock Skyrockets on Major Patent Win
11:15AM  Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod Zacks
09:35AM  Biogen Sees Huge Bounce on MS Drug Patent Ruling
03:40AM  Biogen shares soar after patent victory Financial Times
Feb-03-20 11:39AM  Biogen Investors Face Next Test With Pending Drug Patent Ruling Bloomberg
05:03AM  Biogen Inc. Just Released Its Full-Year Earnings: Here's What Analysts Think Simply Wall St.
Jan-30-20 04:24PM  Biotech Giant Biogen Banks On Alzheimer's Approval In 2020 Outlook Investor's Business Daily
04:07PM  US Stocks Choppy on Thursday
03:31PM  Biogen Reports Strong 4th-Quarter Earnings and Growth Potential
02:55PM  Coronavirus update: First U.S. case of person-to-person transmission confirmed, 195 U.S. citizens in isolation and WHO declares a public health emergency MarketWatch
10:51AM  Biogen (BIIB) Surpasses Q4 Earnings and Sales Estimates Zacks
10:20AM  Biogen touts resilience but gives little guidance on Alzheimer's drug American City Business Journals
09:32AM  Biogen Stock Gets a Lift From Strong Earnings Report
08:34AM  Biogen (BIIB) Q4 Earnings & Sales Beat Estimates Zacks
08:00AM  Slapping Around Martin Shkreli Wont Cut Drug Prices Bloomberg
07:34AM  Biogen's stock rises 2% on Tecfidera sales MarketWatch
07:00AM  Biogen quarterly profit jumps on demand for multiple sclerosis drug Reuters
04:20AM  Biogen Beats Q4 Estimates on Strong Sales of Treatments for MS, Spinal Atrophy
01:56AM  Biogen Earnings, Revenue Beat in Q4
Jan-29-20 02:59PM  Parnassus Endeavor Fund Exits Biogen, Trims Regeneron
12:02PM  Industry vet Holtzman steps down; Decibel retunes strategy American City Business Journals
09:05AM  Novartis Stock Is Rising as Earnings Inch Past Forecasts
08:56AM  Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More Zacks
05:51AM  Did You Manage To Avoid Biogen's (NASDAQ:BIIB) 28% Share Price Drop? Simply Wall St.
Jan-27-20 03:16PM  Looking Back at 2019
11:18AM  Biogen's Alzheimer's Drug Has 'Decent Shot' At FDA Approval, Analyst Says Benzinga
11:08AM  Buy Biogen Stock Now Because Its Alzheimer Drug Has a Decent Shot at FDA Approval
08:10AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4? Zacks
06:05AM  Quench Bio launches with $50M to treat 'missing link' to inflammatory disease American City Business Journals
06:00AM  Biogen Reports Earnings This Week. Heres What To Expect.
Jan-26-20 07:17PM  Adding Biotech ETFs to Your Portfolio Investopedia
Jan-23-20 09:21AM  The one value strategy that wasnt a disaster now favors commodity sector over techs MarketWatch
08:51AM  Roche's Risdiplam Meets Primary Endpoint in Infants Study Zacks
01:18AM  Roche's risdiplam meets primary endpoint in trial of SMA drug in infants Reuters
Jan-21-20 06:21PM  Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe Zacks
02:50PM  Mass. employers earn high marks in LGBTQ-friendly workplace index American City Business Journals
Jan-20-20 05:32PM  Top Long-Term Growth Stocks in the Health Care Sector
Jan-16-20 01:10PM  FDA Risks Sacrificing Its Standards for Speed Bloomberg
05:00AM  Top Picks 2020- Ionis Pharmaceuticals IONS MoneyShow
Jan-15-20 05:50PM  4 High-Quality Health Care Companies for 2020
05:39AM  Alexion pushes 'high-risk, high-reward' ALS strategy amid competitive pressure American City Business Journals
Jan-14-20 01:02PM  Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc. Moody's
09:55AM  Biogen Acquires Early-Stage CNS Drug From Pfizer for $75M Zacks
Jan-13-20 08:46AM  Benzinga Pro's Top 5 Stocks To Watch For Mon., Jan. 13, 2020: WCC, LULU, XLF, TEAM, BIIB Benzinga
07:51AM  Biogen to buy from Pfizer an asset to develop into potential Alzheimer's, Parkinson's treatments MarketWatch
07:30AM  Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimers Disease and Parkinsons Disease from Pfizer Inc. GlobeNewswire
Jan-10-20 08:05PM  Biogen Defends Its Blockbuster Against Mylans Patent Challenge
07:00AM  Biogen signs neuro disease drug deal with Cambridge startup American City Business Journals
Jan-09-20 09:20AM  4 Things to Pay Attention to at the J.P. Morgan Health-Care Conference Next Week
08:00AM  Red-Hot Biotech Stocks Brace For Key Meeting Here's What To Expect Investor's Business Daily
Jan-08-20 07:30AM  Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy PR Newswire
Jan-06-20 09:38AM  Biogen Faces a Looming Patent Decision. Heres How Much Its Stock Could Drop If It Loses.
Jan-02-20 10:08AM  Drug-Price Increases Show Business as Usual Despite Public Pressure
08:41AM  Bristol-Myers, Gilead, Biogen, Other Drugmakers Increased U.S. List Prices on Jan. 1: Report
Jan-01-20 11:47AM  More drugmakers hike U.S. prices as new year begins Reuters
Dec-30-19 11:02AM  Why Biogen Inc. (NASDAQ:BIIB) Looks Like A Quality Company Simply Wall St.
Dec-26-19 11:14AM  2020 Vision: In Biogen, industry could see 1st new Alzheimer's drug in years American City Business Journals
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases, and related therapeutic adjacencies in the United States, Europe, Asia, and internationally. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA, as well as ophthalmology biosimilar products, such as SB11 referencing LUCENTIS and SB15 referencing EYLEA. The company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. It also develops Opicinumab, BIIB091, and BIIB061 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB100, and BIIB110 for neuromuscular disorders; BIIB094 and BIIB054 to treat movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and other diseases; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, BIIB093, and Natalizumab to treat acute neurology; and BIIB074 and BIIB095 for pain. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.004,847033,775Feb 19 06:20 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 15Option Exercise0.001,213015,019Feb 19 06:17 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.0044102,672Feb 19 06:13 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 15Option Exercise0.001,553037,261Feb 19 06:09 PM
Kramer RobinVP, Chief Accounting OfficerFeb 12Option Exercise0.001320282Feb 14 06:37 PM
Karp DanielEVP, Corporate DevelopmentFeb 12Option Exercise0.0096001,224Feb 14 06:36 PM
Guindo ChirfiEVP Glob. Prod Strat and CommFeb 12Option Exercise0.001,68004,375Feb 14 06:34 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.003,54705,021Feb 14 06:32 PM
Galdes AlphonseEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.001,15402,337Feb 14 06:30 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerFeb 12Option Exercise0.001,91903,732Feb 14 06:27 PM
ALEXANDER SUSAN HEVP Chief Legal Off & Corp SecFeb 12Option Exercise0.005,967036,389Feb 14 06:25 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.0011,994031,483Feb 14 06:19 PM
Sandrock AlfredEVP, Research & DevelopmentFeb 12Option Exercise0.005,216014,509Feb 14 06:16 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,30202,219Jan 06 04:14 PM
Kramer RobinVP, Chief Accounting OfficerDec 03Option Exercise0.00840175Dec 05 04:24 PM
Posner Brian SDirectorDec 02Sale292.351,055308,4296,995Dec 03 05:58 PM
Guindo ChirfiEVP Glob. Prod Strat and CommDec 01Option Exercise0.0054302,855Dec 03 05:59 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0017902,295Aug 05 04:20 PM
Karp DanielEVP, Corporate DevelopmentJul 02Option Exercise0.001960322Jul 05 04:51 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,12608,525Jun 04 04:56 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,480022,487May 06 04:20 PM
DENNER ALEXANDER JDirectorMay 02Buy231.2438,0008,787,120643,000May 02 05:06 PM
DENNER ALEXANDER JDirectorMay 01Buy229.4630,0006,883,800605,000May 02 05:06 PM
Vounatsos MichelChief Executive OfficerMay 01Buy231.484,3511,007,16921,007May 02 04:30 PM
DENNER ALEXANDER JDirectorApr 30Buy229.2550,34211,540,904575,000May 02 05:06 PM
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM